Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was CNY 21,927.56 million compared to CNY 18,214.99 million a year ago. Net income was CNY 45.21 million compared to CNY 147.3 million a year ago.

Basic earnings per share from continuing operations was CNY 0.01 compared to CNY 0.03 a year ago. Diluted earnings per share from continuing operations was CNY 0.01 compared to CNY 0.03 a year ago.